Connect with us

Hi, what are you looking for?


Buy Procore shares for a 41% return in 12 months: Goldman Sachs

Shares of Procore Technologies Inc (NYSE: PCOR) were seen trading up nearly 10% today after a Goldman Sachs analyst turned bullish on the construction management software company.

Procore shares could climb to $75

On Thursday, Kash Rangan raised his rating on the Carpinteria-headquartered firm to “buy” and announced a price objective of $75 that suggests about a 41% upside on its previous close.

The bullish call arrives only hours after Procore Technologies Inc reported strong results for its first financial quarter.

Since construction is a low-margin business, Procore’s customers by default bid on a wide array of projects in various industries to reduce concentration risk, which benefits Procore’s own diversification efforts.

The analyst now expects this construction technology company to grow its revenue by 29% this year. Procore shares are down 20% versus their year-to-date high at writing.

Why else is he bullish on Procore stock?

Kash Rangan likes this software as a service (SaaS) company because the construction industry lacks streamlined means of digitisation.

Other reasons cited for the constructive view on Procore shares include its backlog of customers and a hint of positive sentiment from the management. The analyst said in his research note:

Customer backlog provides insulation from near-term demand degradation since its customer base has to work through existing backlogs before slowdown in construction would impact their ability to land new projects.

He remains bullish on the cloud stock even though WCM Investment Management recently revealed to have trimmed its exposure to Procore Technologies Inc by 7.2% in the fourth quarter.

The post Buy Procore shares for a 41% return in 12 months: Goldman Sachs appeared first on Invezz.

Enter Your Information Below To Receive Free Trading Ideas, Latest News And Articles.

    Your information is secure and your privacy is protected. By opting in you agree to receive emails from us. Remember that you can opt-out any time, we hate spam too!

    You May Also Like

    Latest News

    Rep. Jennifer Wexton (D-Va.) announced on Tuesday that she has been diagnosed with Parkinson’s Disease. “If there’s one thing that Democrats and Republicans can...

    Latest News

    After Dianne Feinstein announced she’d contracted the shingles in early March, her staff said she planned to return to the Senate within a matter...


    A U.S. District Court judge has ruled that Elizabeth Holmes, founder and CEO of the disgraced blood-testing company Theranos, cannot remain free on bail...

    Latest News

    SEOUL, South Korea — When a group of American lawmakers arrived in South Korea for meetings with government and military officials, President Yoon Suk-yeol...

    Disclaimer:, its managers, its employees, and assigns (collectively “The Company”) do not make any guarantee or warranty about what is advertised above. Information provided by this website is for research purposes only and should not be considered as personalized financial advice. The Company is not affiliated with, nor does it receive compensation from, any specific security. The Company is not registered or licensed by any governing body in any jurisdiction to give investing advice or provide investment recommendation. Any investments recommended here should be taken into consideration only after consulting with your investment advisor and after reviewing the prospectus or financial statements of the company.

    Copyright © 2022 All Rights Reserved.